Navigation Links
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Date:1/18/2008

ate to severe disease. Psoriasis is a serious, sometimes painful autoimmune disease resulting in inflamed, scaly, red skin lesions known as plaques, which may crack and bleed. In addition to visible symptoms, people with psoriasis may suffer from poor self-image and social isolation, and even feelings of depression, such as sadness and despair. Recent research also suggests psoriasis may be associated with other serious health risks. Up to 30 percent of psoriasis patients develop psoriatic arthritis, which combines skin symptoms with arthritis symptoms, including joint pain and inflammation.

"The approval of HUMIRA is excellent news for patients suffering from psoriasis, which can have a profound physical and emotional impact on a person's life," said Alan Menter, M.D., chairman, division of dermatology, Baylor University Medical Center, Dallas. "HUMIRA offers dermatologists an important new therapeutic option that has been shown to help alleviate a range of psoriasis signs and symptoms, including redness, scaling and itching, in many psoriasis patients."

HUMIRA for Plaque Psoriasis

The approval of HUMIRA is based on data from more than 1,400 adult patients in two pivotal trials -- REVEAL and CHAMPION. Both studies evaluated the efficacy and safety of HUMIRA in clearing skin in moderate to severe adult plaque psoriasis patients versus placebo. In addition, CHAMPION compared a biologic medication to methotrexate, a standard systemic treatment for psoriasis. REVEAL results were published in the Journal of the American Academy of Dermatology in January 2008 and CHAMPION results were published online in the British Journal of Dermatology.

In each trial, reduction in disease activity was determined by the Psoriasis Area and Severity Index (PASI) and Physician's Global Assessment (PGA). The PASI score measures the extent and severity of psoriasis. PASI may be calculated before and after a treatment period to determine efficacy; for example, a P
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... its second quarter 2014 financial results on Monday, August ... markets. Following the announcement, members of the management team ... results and provide a general corporate update at 4:30 ... can be obtained as follows: Monday, August ...
(Date:7/25/2014)... 25, 2014  Corporate libraries are constantly being faced ... in technology and how to cope with flat or ... pharmaceutical and medical device industries are increasingly finding it ... services they provide. According to recent ... many forces of change that leading corporate libraries are ...
(Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Forces of Change Reshaping Corporate Libraries & Information Services 2Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
... N.C., March 4, 2011 The pressure for a ... greater with organizations across the pharmaceutical sector facing pipeline ... Facing an ever-changing launch landscape, product launch leaders ... new therapies through the labyrinth of regulatory and marketplace ...
... 2011 Cardica, Inc. (Nasdaq: CRDC ) ... stapling device developed by Cardica has received CE Mark ... marking process, Cardica has obtained a Full Quality Assurance ... this certification, after successful completion of development, Cardica can ...
Cached Medicine Technology:Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 3Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 4
(Date:7/28/2014)... With California in a record draught ... that a fire blanket that is over ... development by SunSeeker Enterprises, Inc. The fire blanket—utilizing the ... the extreme heat of re-entry into the Earth's atmosphere—will ... , “Our firefighters routinely lay their very lives on ...
(Date:7/28/2014)... July 28, 2014 At some point in ... where they’re forced to contact the authorities. Distinguishing the ... than it initially seems. , Not every dangerous situation is ... stolen, a person get mugged, or a bank get held ... leading onlookers to be more passive than they otherwise should. ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
(Date:7/28/2014)... July 28, 2014 The report ... Applications (Food & Beverages, Cleaning Agents, Bio-Fuel, Animal ... to 2018” defines and segments the global industrial ... global value for industrial enzymes. It also identifies ... enzymes market with analysis of trends, opportunities, burning ...
(Date:7/28/2014)... School of Medicine (BUSM) report variants in a new ... Alzheimer,s disease (AD). The discovery of this novel genetic ... target PLXNA4 specifically. These findings appear in the ... frequent age-related dementia affecting 5.4 million Americans including 13 ... than 40 percent of people age 85 and older. ...
Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Researchers identify potential biomarker for AD 2
... A recent study estimates that nearly 30,000 men will ... study offers hope for these patients: // The combination ... improves survival rates. ,AST inhibits the release of ... three years of AST with radiation therapy has been ...
... compression stockings can reduce complications after a blood clot ... uncomfortable .// ,Some of the common complications with ... leg include swelling, skin discoloration, numbness, chronic pain, hardening ... suggested that elastic stockings could help patients with blood ...
... of people worldwide . It is the most common form ... are still unknown and there is no cure. ,New ... to treating Alzheimer’s disease. A team of researchers tested ... were given sage oil capsules, and some were given placebos. ...
... to researchers a group of cells, called satellite cells, ... older people maintain // their youthfulness. These cells rescue ... They also generate new cells for future repairs. Previous ... protein called Notch is activated by another protein called ...
... Chronic obstructive pulmonary disease, an often neglected disease of the ... The vast majority of people with the disease are smokers. ... from wood fires also comes into play in some cases. ... in fact, it will be the third leading cause of ...
... news for the many adults and children who have endured ... ,Developing a vaccine to prevent group A streptococcal infections has ... years. Group A streptococcus is responsible for a variety of ... most common. ,The vaccine trial included 28 adults ...
Cached Medicine News:
The Advance Unicompartmental Knee System is designed with bone conserving femoral and tibial components that provide reproducible results within a minimal incision. Uni metal backed tibial component....
...
...
... Severe revision options for the knee and ... modular system for the knee and hip ... that include surgical indication, implant selection, connection ... individual needs. This system addresses the needs ...
Medicine Products: